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Objectives: Electroconvulsive therapy (ECT) is considered to be one of the most effective 
treatments in psychiatry. Currently, three medications for anesthesia are used routinely during 
ECT: propofol, etomidate, and thiopental. The objective of this study was to evaluate the effects 
of the anesthetics used in ECT on seizure threshold and duration, hemodynamics, recovery from 
ECT, and immediate side effects.
Methods: Our study is a retrospective cohort study, in which a comparison was made between 
three groups of patients who underwent ECT and were anesthetized with propofol, etomidate, 
or thiopental. The main effect compared was treatment dose and seizure duration. All patients 
were chosen as responders to ECT.
Results: Data were gathered about 91 patients (39 were anesthetized with thiopental, 29 with 
etomidate, and 23 with propofol). Patients in the thiopental group received a lower electrical 
dose compared to the propofol and etomidate group (mean of 459 mC compared to 807 mC and 
701 mC, respectively, P,0.001). Motor seizure duration was longer in the thiopental group com-
pared to propofol and etomidate (mean of 40 seconds compared to 21 seconds and 23 seconds, 
respectively, P=0.018). Seizure duration recorded by electroencephalography was similar in the 
thiopental and etomidate groups and lower in the propofol group (mean of 57 seconds in both 
groups compared to 45 seconds, respectively, P=0.038).
Conclusion: Patients who were anesthetized with thiopental received a lower electrical treat-
ment dose without an unwanted decrease in seizure duration. Thiopental might be the anesthetic 
of choice when it is congruent with other medical considerations.
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Introduction
Electroconvulsive therapy (ECT) is considered to be one of the most effective treat-
ments in psychiatry. Currently, three medications for anesthesia are used routinely 
during ECT: propofol, etomidate, and thiopental. Our objective in this study was to 
evaluate the different effects of the anesthetics used in ECT in order to suggest the 
preferred anesthetic medication for this procedure.
We retrospectively compared three groups of patients who underwent ECT and 
were anesthetized with propofol, etomidate, or thiopental. All patients were chosen as 
clinical responders to ECT. We chose seizure threshold and duration, hemodynamics, 
recovery from ECT, and immediate side effects as the outcomes.
Our hypothesis was that the patients who were anesthetized with thiopental received 
a lower electrical treatment dose without an unwanted decrease in seizure duration. 
We concluded that thiopental might be the anesthetic of choice when it is congruent 
with other medical considerations.Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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The opinions concerning ECT for a variety of psychiatric 
disorders are diverse, and they range from researchers who 
claim that there is a high probability that ECT is ineffective 
and causes long-term side effects1 to clinicians who claim that 
ECT is safe and is the most effective treatment in psychiatry.2,3 
The indications for ECT are major depression, a manic state, 
acute psychosis, and catatonia.4 The treatment procedure is 
performed with short-term general anesthesia under the influ-
ence of neuromuscular-blocking medication by placing two 
electrodes on the temples and/or the forehead of the patient 
and delivering electrical pulses between the electrodes in 
order to induce a generalized convulsion.5
The physiological side effects and aftereffects of ECT 
include fatigue, generalized weakness, vertigo, amnesia, 
confusion, agitation, and headaches.6 The hemodynamic 
effects include an elevation in the systolic blood pressure and 
pulse rate,7 and in certain cases arrhythmias.8 The general-
ized convulsion causes myoclonic seizures, fractures, and 
dislocations of the spine and the long bones, and muscle 
and joint pain.9 The standard use of neuromuscular-blocking 
medication (eg, succinylcholine) prevents the fractures and 
dislocations noted above, but does not prevent muscle and 
joint pain. In addition, there is a potential for dental dam-
age and lacerations of the oral cavity. Side effects that are 
attributed to stimulation of the vagus nerve are sialorrhea, 
nausea, and vomiting. Anticholinergic drugs (eg, atropine) 
are used to minimize these side effects.6
Anesthetics have been used in ECT since the 1950s. The 
anesthesia is used to avoid unpleasant feelings the patient 
may have during convulsion inducement; it prevents the 
sensation of general paralysis after the administration of 
neuromuscular-blocking drugs and lowers the opposition to 
therapy.10 The anesthetic of choice until the mid-2000s was 
methohexital because of its proven safety profile, effective-
ness, and relatively low cost.4 However, a lack of availability 
of methohexital has led to the use of other anesthetics.
Propofol is an anesthetic that is administered intrave-
nously for general anesthesia and is widely used for proce-
dures done under anesthesia.11 This anesthetic causes a rapid 
and smooth entry into unconsciousness and is linked to a 
rapid regaining of consciousness. Propofol has a research-
based and accepted safety profile. Common side effects are 
cardiovascular depression, pain during injection, bradycardia, 
and apnea in the minutes after injection.
Etomidate is an anesthetic that is administered intrave-
nously for sedation and general anesthesia.12 It enters the 
central nervous system rapidly and is cleared rapidly, which 
makes it effective for short-term anesthesia. Etomidate causes 
a decrease in the cerebral metabolic rate, cerebral blood flow, 
and intracranial pressure. It has been suggested in the past that 
etomidate has neuroprotective properties.13 Respiratory and 
cardiovascular function might be slightly depressed by eto-
midate in an insignificant manner. Regarding the endocrine 
system, it can cause adrenal suppression for a few hours and 
a decrease in the production of adrenocortical hormones such 
as cortisol. Additional side effects are nausea and vomiting 
during recovery from anesthesia, myoclonic activity, and 
pain during injection.
Thiopental is a barbiturate that is used for general anesthesia, 
for the treatment of ischemic brain injury, and for the treatment 
of neurosurgical situations such as high intracranial pressure.14 
In high doses, it can be used to treat status epilepticus that is 
refractory to initial pharmacological treatment. Like etomidate, 
in the central nervous system thiopental causes a decrease in 
the cerebral metabolic rate, cerebral blood flow, and intracranial 
pressure. Its effects on the cardiovascular system are a decrease 
in the mean arterial blood pressure and a decrease in cardiac 
output. Significant side effects of thiopental are laryngeal spasm 
and respiratory depression. Benign allergic skin reactions are 
common, but a serious allergic reaction is rare.
In a comparison between propofol and etomidate,15 
differences were found between motor seizure duration as 
observed by a physician and as recorded by electroencepha-
logram (EEG). Seizure durations were shorter for patients 
under the influence of propofol as compared to patients under 
the influence of etomidate. In addition, the recovery time 
and the length of stay in the recovery room were longer for 
patients anesthetized with etomidate, but these findings were 
not statistically significant. Propofol was also compared to 
thiopental,16 and seizure durations were also shorter for the 
propofol group (motor seizure duration and seizure duration 
on EEG). There was no evident difference in the clinical 
efficacy of ECT among patients anesthetized with different 
anesthetics.15,16 In a study that compared the effects of these 
three anesthetics on healthy subjects, etomidate had no influ-
ence on hemodynamic measures.17 Propofol and thiopental 
caused a decrease in systolic blood pressure and an increase 
in pulse rate in the minutes after injection.
study objective
Our objective in this study was to compare the effects of 
the anesthetics used today for ECT (propofol, etomidate, 
and thiopental) on the course of treatment, hemodynamic 
measures, recovery time, and immediate side effects after 
treatment. According to previous research, we assumed that 
patients who were anesthetized with propofol would receive Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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a higher electrical treatment dose, and their seizure duration 
would be shorter. We assumed that patients who were anes-
thetized with propofol and thiopental would show a smaller 
increase in pulse and blood pressure, which accompanies 
ECT. We had hypothesized that the recovery time might be 
shorter for patients anesthetized with propofol and thiopental. 
In addition, we would like to clarify the side effects profile 
for each anesthetic.
Materials and methods
This is a retrospective cohort study. Our study was approved 
by the Beer Yaakov-Ness Ziona Mental Health Center insti-
tutional review board.
study population
The population sampled for this study comprises all the 
patients treated in the ECT unit in the Beer Yaakov-Ness Ziona 
Mental Health Center between the years 2008 and 2012. We 
gathered information about patients who met the following 
inclusion criteria: 1) was treated in the ECT unit between 2008 
and 2012; 2) had a good response to the treatment as evaluated 
clinically by the staff of the hospitalizing ward (ie, the patient 
was categorized as responsive to ECT); 3) anesthetized during 
ECT with propofol, etomidate, or thiopental; 4) over age 18 at 
time of treatment; 5) had three consecutive treatments with an 
identical treatment dose for a comparison among these treat-
ments; 6) treated during hospitalization (because there is more 
available information on hospitalized patients); 7) all needed 
data were recorded in the patient’s medical file.
study variables
We gathered data about 91 patients (39 were anesthetized 
with thiopental, 29 with etomidate, and 23 with propofol). 
Patients in the thiopental group received a lower electrical 
dose compared to the propofol group and the etomidate 
group (mean of 459 mC compared to 807 mC and 701 mC, 
respectively, P,0.001). Motor seizure duration was longer in 
the thiopental group compared to the propofol and etomidate 
groups (mean of 40 seconds compared to 21 seconds and 
23 seconds, respectively, P=0.018). Seizure duration recorded 
by electroencephalography was similar in the thiopental and 
etomidate groups and lower in the propofol group (mean of 
57 seconds in both groups compared to 45 seconds, respec-
tively, P=0.03).
ecT procedure
All the patients were recruited from acute wards 
and   completed a medical check-up before the ECT   
treatment. This work-up includes blood tests, chest X-ray, 
electrocardiogram, neurological examination, and general 
physician’s and anesthesiologist’s clearance. Patients with 
existing health problems need clearance from the specialist 
in order to undergo ECT treatment. After completing the 
work-up and signing the treatment consent form, patients 
were not allowed to eat or drink for 8 hours before the 
treatment. All patients received 1% intramuscular atropine 
30 minutes before the treatment. ECT was performed 
according to criteria from The   Practice of Electroconvul-
sive Therapy:   Recommendations for   Treatment, Training, 
and Privileging.4 The spECTrum 5000M (Mecta; Portland, 
OR, USA) machine was used to perform the electrical 
impedance.
The patients were divided into groups according to 
the anesthetic used during ECT: propofol, etomidate, or 
thiopental. The anesthesiologist selected each patient’s 
anesthetic according to the patient’s medical background, 
additional medications, time to recovery after the first treat-
ment, and the patient’s response to the anesthetic in the past. 
Thiopental was given 1.5 × body weight (120mg–200mg), 
propofol 0.6 × body weight (60mg–100mg), and etomidate 
0.1 × body weight (8mg–12mg) of the patient. The primary 
outcomes were the course of ECT: treatment electrical dose 
in mC and motor seizure duration as recorded by EEG. 
The effectiveness of the seizure was defined as minimum 
25 seconds of clinical seizure and minimum 30 seconds of 
EEG-recorded seizure. The secondary outcomes were the 
effect on heart rate and blood pressure. We routinely used the 
blood pressure cuff method to measure the anesthetic depth 
and scoline administration. Additional outcomes were the 
amount of time until transfer to the recovery room and the 
frequency of side effects immediately after treatment. Sex, 
age at the first treatment in the study, and information about 
cardiovascular disease were gathered as possible confounders. 
For each patient, data were gathered about three consecutive 
treatments. All patients were treated with 1 mg of atropine 
administered intravenously and a dose of succinylcholine 
(40, 50, 70, or 100 mg according to the patient’s weight and 
ethnicity, and the anesthesiologist’s considerations), also 
administered intravenously. The three treatments undertaken 
for each patient were identical in regard to the type and dose 
of anesthetic, the dose of succinylcholine, and the dose of 
electrical treatment.
Data sampling
The data for this study were taken from the medical records 
archive in Beer Yaakov-Ness Ziona Mental Health Center. Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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All the study variables are routinely documented by the staff 
in the ECT unit.
Patients who fit the inclusion criteria were identified 
by reviewing the medical records of all patients who were 
admitted for treatment in the ECT unit from June 2008 until 
October 2012. Data were gathered until there were enough 
patients in each study group according to the predefined 
sample size (detailed in the following section). The treat-
ments included for each patient were the three most recent 
consecutive treatments with identical parameters.
statistical analysis
Sample size was calculated using the software Power 
and Precision version 4.1 by SPSS (IBM Corporation, 
Armonk, NY, USA). Sample size calculation was done 
for a one-way analysis of variance test comparing three 
groups. A sample of 66 patients was calculated (22 in each 
group) in three groups. This would provide an effective 
size of 0.4 using Cohen’s F-statistic, meaning that at least 
40 percent of the variance in the dependent variable would 
be explained by the different anesthetic groups; we con-
sidered type 1 and type 2 error probabilities of 0.05 and 
0.20, respectively.
As previously stated, data were sampled from three 
consecutive treatments. The value taken for the statistical 
analysis was the average of the outcome in these treatments. 
For numerical variables analysis, we used the analysis of 
variance test. For categorical variables, we used the Pearson’s 
chi-square test. In order to estimate the influence of con-
founding variables, we used a model of linear regression. All 
statistical analysis was done using SPSS software, version 
19 (IBM Corporation).
Results
characteristics of the patients
Between June and October 2012, data were gathered about 
91 patients who fit the inclusion criteria for this study. The 
psychiatric diagnoses of all participants are displayed in 
  Figure 1. The patients were divided as follows: 39 patients 
were anesthetized with thiopental during ECT, 29 patients with 
etomidate, and 23 patients with propofol. Characteristics of 
the different groups are shown in Table 1.
The propofol patient group was different from the other 
groups in a few characteristics. This group had a higher 
percentage of women (88% versus [vs] 61% and 59% in 
the thiopental and etomidate groups, respectively), a higher 
average age (62 vs 45 and 47 in the thiopental and etomidate 
groups, respectively), and a higher percentage of patients 
with cardiovascular disease (48% vs 26% and 14% in the 
thiopental and etomidate groups, respectively). The anesthetic 
used for ECT is chosen by the anesthesiologist in a nonran-
domized manner, and that might explain the differences in 
characteristics between the groups.
Table 1 characteristics of all patients
Characteristic Thiopental 
(N=39)
Propofol 
(N=23)
Etomidate 
(N=29)
Age during the first  
treatment‡, years*
45±16 62±8 47±18
Male sex, number (%)** 15 (39) 3 (12) 17 (59)
Psychiatric diagnosis, number (%)
  schizophrenia 18 (46) 16 (64) 24 (83)
    acute and transient  
psychotic disorder
2 (5) 1 (4) 0
    schizoaffective disorder 4 (10) 3 (12) 1 (3)
    Bipolar disorder 1 (3) 0 1 (3)
    Depressive episode 6 (15) 3 (12) 1 (3)
    recurrent depressive  
disorder
8 (20) 2 (8) 2 (7)
cardiovascular diseaseii,  
number (%)***
10 (26) 12 (48) 4 (14)
(N=35) (N=23) (N=28)
systolic blood pressure  
before treatment, mmhg†
139±20 148±21 148±24
Diastolic blood pressure  
before treatment, mmhg†
84±9 85±11 89±14
(N=33) (N=22) (N=28)
heart rate before treatment,  
beats per minute†
94±16 99±21 101±15
Notes: The symbol ± is used to describe an average and standard deviation; the 
average is on the left side. *Statistically significant difference in one-way analysis 
of  variance  test  (P,0.001);  **statistically  significant  difference  in  Pearson’s  chi-
square test (P=0.002); ***statistically significant difference in Pearson’s chi-square 
test (P=0.019); †an average of three consecutive treatments with identical treatment 
dose;  ‡the first out of three treatments sampled for this study;  iicardiovascular 
disease includes diabetes, dyslipidemia, and chronic hypertension.
Recurrent
depressive
disorder
13%
Depressive
episode
11%
Acute and
transient
psychotic
disorder
3%
Bipolar
disorder
2%
Schizoaffective
disorder
9%
Schizophrenia
62%
Figure  1  Psychiatric  diagnoses  according  to  the  International  Classification  of 
Diseases (icD) 10 for all patients.Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
387
comparison of anesthetics in ecT
Treatment course
Outcome variables are listed in Table 2. Stimulus dosage was 
459±308 mC with thiopental, and was higher with propofol 
(807±406 mC) and etomidate (701±397 mC). Patients’ aver-
age clinical seizure time was 40±12   seconds with thiopen-
tal, 32±8 seconds with propofol, and 34±13 seconds with 
etomidate. EEG-recorded seizure time was 57±16 seconds 
with thiopental, 45±16 seconds with propofol, and 57±23 
seconds with etomidate. There was a statistically significant 
difference among the groups in the electrical treatment 
dose and seizure duration. Patients in the thiopental group 
received a lower treatment dose compared to the other 
groups (P,0.001). In addition, motor seizure duration was 
higher in the thiopental group (P=0.018). The seizure dura-
tion on EEG was similar in the thiopental and etomidate 
group and lower in the propofol group (P=0.038).
Patients who were anesthetized with propofol were 
believed to receive a higher treatment dose, but in actual fact 
patients in the propofol and etomidate groups received simi-
lar treatment doses, and patients in the thiopental group were 
treated with a lower dose. Also, we assumed that patients 
who were anesthetized with propofol would experience 
shorter seizures, but the average motor seizure duration was 
similarly lower in the propofol and etomidate groups. On the 
other hand, average seizure duration as recorded on EEG was 
lower in the propofol group alone. The discrepancy between 
average motor seizure duration and average seizure duration 
on EEG is relevant to clinicians and is probably related to 
the physician’s observation of the patient. However, we do 
not believe that there might be an observational confirmation 
bias in clinically assessing motor seizure time.
hemodynamic changes
Diastolic blood pressure remained stable in the etomidate 
group, as opposed to an elevation after treatment in the other 
groups (P=0.016). Systolic blood pressure was elevated after 
treatment in all three groups. Pulse rate decreased in the 
etomidate group after treatment and remained stable in the 
other groups (P=0.013).
In regards to hemodynamic changes, the study results 
are contrary to our expectations. We assumed that in the 
etomidate group, there would be a more significant eleva-
tion in blood pressure and pulse, but in actual fact, there 
was a decrease in diastolic blood pressure and a decrease in 
heart rate. It is possible that these outcomes, which were not 
anticipated considering past studies, arose from differences 
among the groups that we have not described in this retro-
spective study. Surprisingly, etomidate seemed to have a 
similar effect on blood pressure as other anesthetics.
course after treatment
Time until transfer to the recovery room was almost identical 
among the three groups. Regarding immediate side effects, 
the only side effect documented was agitation. There was no 
difference in the percentage of patients who experienced side 
effects among the three groups.
confounders
The possible effects of confounding variables were evaluated 
using linear regression (results are listed in Table 3).
We evaluated as confounders variables that were cor-
related with one or more of the treatment groups. The vari-
ables are age during the first treatment in the study, sex, and 
Table 2 Outcomes*
Outcome Thiopental Propofol Etomidate P-value
N Average ± SD N Average ± SD N Average ± SD
Treatment dose, mc 39 459±308 23 807±406 29 701±397 ,0.001‡
Motor seizure duration, seconds 32 40±12 21 32±8 23 34±13 0.018‡
seizure duration recorded on eeg 35 57±16 21 45±16 25 57±23 0.038‡
change in systolic blood  
pressure, mmhg†
30 14±12 23 12±20 28 9±19 0.47
change in diastolic blood  
pressure, mmhg†
29 8±13 23 5±12 28 -1.4±11 0.016‡
change in heart rate,  
beats per minute†
29 2±18 18 1±19 27 -11±14 0.013‡
Time until transfer to  
recovery room, minutes
20 11±4 11 11±3 15 12±2 0.61
N Number (%) N Number (%) N Number (%) P-value
Number of patients who experienced 
agitation after treatment
39 6 (15) 23 2 (9) 29 6 (21) 0.43
Notes: *For each patient, the data used for statistical analysis is the average of the outcome in three consecutive treatments; †change was calculated by subtracting the value 
before treatment from the value after treatment; ‡statistically significant difference in a one-way analysis of variance test.
Abbreviations: eeg, electroencephalography; sD, standard deviation.Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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cardiovascular disease. Age was the only variable found to 
have a statistically significant effect.
In addition to the anesthetic used, age was found to have 
an effect on the average treatment dose and on motor seizure 
duration. This effect does not explain the similarity between 
the propofol and etomidate groups or the difference from the 
thiopental group and could be related to the basic difference 
in characteristics between the study groups.
Discussion
According to our PubMed/Ovid/ResearchGate search, 
only a few articles have been published that compared 
these three anesthetics in ECT treatment. Our study aimed 
to demonstrate differences among these three agents. 
A retrospective study by Eser et al18 compared these 
anesthetics’ effects in ECT, but it included also patients 
anesthetized with methohexital. The authors concluded 
that thiopental and propofol are the most suitable induction 
agents during ECT.
A small randomized double-blind study (N=30) by 
Rosa et al19 compared the effects of propofol, etomidate, 
and thiopental in ECT, but regarded only the cardiovas-
cular effects; no differences were found. Another study 
by Rosa et al20 with the same sample size compared the 
effects of these three medications on ECT, but mainly 
regarded recovery time. Propofol seemed to have the best 
recovery profile.
In our study, there was a statistically significant differ-
ence in the treatment course (as measured by treatment dose 
and seizure duration) among the groups. Patients who were 
anesthetized with thiopental received a lower treatment dose 
without an unwanted decrease in seizure duration; there-
fore, we conclude that thiopental might be the anesthetic 
of choice when other medical considerations allow its use. 
Etomidate caused a decrease in pulse rate after ECT and 
stabilized the diastolic blood pressure; however, this finding 
was not expected in light of the current literature.17 In order 
to continue studying this issue, there is a need for research 
in which the difference among the groups can be neutralized 
(using randomization or case-control studies). There were 
no differences in the course of recovery among the different 
anesthetics.
The power of this study is that it was conducted in one 
electroconvulsive therapy unit with much experience in treat-
ing and following psychiatric patients. Because standard and 
common measures were used, the inner validity of this study 
should be high. In addition, because the assumptions and 
study population are well defined, conclusions can be made 
about similar populations undergoing ECT. Nonetheless, 
this study has weak points as well. First of all, this is a 
Table 3 linear regression results for possible confounders
Independent variable 
Confounder
N F-value P-value Unstandardized  
effect (B)
SD t-value P-value
Treatment dose 91 7.363 .0.001*        
  Age during first treatment 8.6 mc/year 2.7 3.189 0.002**
  Female sex       101.8 mc 85 1.198 0.234
  cardiovascular disease -112.2 mc 96.2 -1.166 0.247
Motor seizure duration 76 3.376 0.009*        
  Age during first treatment -0.2 sec/year 0.1 -2.357 0.021**
  Female sex       -1.157 sec 3.3 -0.351 0.726
  cardiovascular disease 0.681 sec 3.1 0.217 0.829
seizure duration on eeg 81 2.619 0.031*        
  Age during first treatment -0.2 sec/year 0.2 -1.315 0.192
  Female sex       -8.2 sec 4.7 -1.756 0.083
  cardiovascular disease 3.377 sec 5.4 0.626 0.533
change in diastolic blood pressure† 80 3.147 0.012*        
  Age during first treatment -0.2 mmhg/year 0.1 -2.003 0.049
  Female sex       5.6 mmhg 3.2 1.75 0.084
  cardiovascular disease -2.5 mmhg 3.6 -0.691 0.492
change in heart rate† 74 2.653 0.03*        
  Age during first treatment -0.2 bpm‡ 0.2 -1.346 0.183
  Female sex       6.3 bpm 4.8 1.333 0.187
  cardiovascular disease       6.1 bpm 5.5 1.097 0.276
Notes: *Statistically significant difference in one-way analysis of variance; **statistically significant difference for a two-tailed t-test (P,0.05); †change was calculated by 
subtracting the value before treatment from the value after treatment.
Abbreviations: bpm, beats per minute; eeg, electroencephalography; sD, standard deviation; sec, seconds.Neuropsychiatric Disease and Treatment
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retrospective study without randomization of patients to 
study groups, and thus it might have a selection bias. This is 
also a study without blinding, so it might have an observa-
tional confirmation bias as well. In addition, in the patient’s 
medical records there is only a brief report of the influence 
of ECT on their clinical or psychiatric states in a way that 
can be gathered and assessed for research. From the medical 
records, it can be inferred that the patients responded in a 
positive manner to ECT, but there are no questionnaires or 
reporting templates that might give a more objective assess-
ment of their clinical states. It is important to mention that 
previous studies found no difference in the efficacy of ECT 
when using different anesthetics.15,16
Conclusion
Thiopental might be the proper medication for induction in 
ECT when other medical considerations allow its use. We 
hope that this study will help medical professionals to choose 
the best anesthetic for each patient.
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